Michael Gelband’s Moderna MRNA Stock Holding History

Michael Gelband’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-24,400	Closed	-$2.9M	–	1915
2024 Q2	$2.9M	Buy	+24,400	New	+$3.09M	0.02%	646

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Michael Gelband's MRNA Position: Q2 2026 in Review

Michael Gelband sold out of Moderna (MRNA) in Q2 2026, closing a stake of 13,099 shares — an estimated $665K sold.

Michael Gelband first reported a position in MRNA in Q1 2020 and held it in 15 quarters. The position peaked at $79.1M in Q2 2021. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Michael Gelband reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 13,099 Moderna shares in Q2 2026, an estimated $665K.
Michael Gelband first reported a position in Moderna in Q1 2020 and held it in 15 quarters.
Michael Gelband's Moderna position peaked at $79.1M in Q2 2021.
775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.